18,416 Shares of Gilead Sciences, Inc. $GILD Bought by Edgestream Partners L.P.

Edgestream Partners L.P. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,416 shares of the biopharmaceutical company’s stock, valued at approximately $2,745,000.

Several other institutional investors have also recently modified their holdings of GILD. BlackRock Inc. acquired a new position in Gilead Sciences in the 2nd quarter worth approximately $15,393,785,000. State Street Corp raised its position in Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after buying an additional 1,357,967 shares during the last quarter. Amundi lifted its stake in Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after acquiring an additional 1,018,976 shares during the period. Legal & General Group Plc acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $1,316,606,000. Finally, Deutsche Bank AG acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $918,387,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, EVP Wettan Keeley M. Cain sold 3,399 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the sale, the executive vice president directly owned 5,360 shares of the company’s stock, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $170.55, for a total value of $4,775,400.00. Following the completion of the sale, the insider directly owned 110,684 shares in the company, valued at approximately $18,877,156.20. The trade was a 20.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 237,709 shares of company stock worth $39,799,137 in the last 90 days. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently commented on GILD shares. Scotiabank upped their price objective on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Jefferies Financial Group set a $196.00 price target on shares of Gilead Sciences in a report on Wednesday, November 4th. Finally, Wells Fargo & Company upped their price target on shares of Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $171.63.

Read Our Latest Research Report on Gilead Sciences

Gilead Sciences Stock Down 0.1%

GILD stock opened at $166.33 on Friday. The firm has a market cap of $206.30 billion, a PE ratio of -52.64 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The firm’s fifty day moving average is $157.26 and its 200 day moving average is $142.46. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the previous year, the company earned $2.47 earnings per share. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is currently -103.80%.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.